Breaking Free from the Itch/Scratch Cycle in PN and AD: Enhancing Patient Outcomes for Atopic Dermatitis and Prurigo Nodularis

1.00 AMA PRA Credits
Overview
Learning Objectives
CME/ Information
Faculty and Disclosures
Instructions

Program Overview

This innovative, online educational series focuses on improving outcomes for patients with Atopic Dermatitis (AD) and Prurigo Nodularis (PN) through a comprehensive, interactive learning platform. Offered by the Virtual Dermatology Center, in collaboration with Iridium CE and Global Education Group, the program leverages advanced AI patient simulations and supportive resources to enhance clinical skills and patient care.

Participants will navigate through multidimensional case studies within a simulated Virtual Dermatology Clinic setting, engaging with AI-driven patient scenarios that simulate real-world clinical environments. These interactions are designed to enhance diagnostic and communication skills, as well as clinical decision-making through activities such as multidisciplinary consultations, laboratory test interpretations, and managing electronic medical records.

Target Audience

This program is intended for U.S. physicians, nurse practitioners, and physician assistants in dermatology clinical practice involved in assessing and managing itch in patients with prurigo nodularis and atopic dermatitis.  

Supporter Acknowledgement

This educational activity is supported by an independent educational grant from Incyte Corporation and Sanofi and Regeneron Pharmaceuticals .

Learning Objectives

Upon completion of this activity, the participant should be able to:
  • RECOGNIZE itch as a critical and immediate treatment target due to the significant burden it places on patients with prurigo nodularis (PN) and atopic dermatitis (AD). 
  • ANALYZE clinical outcomes from real-world U.S.-based practices. 
  • IDENTIFY how itch is measured and assessed in diverse patient populations. 
  • INTEGRATE best practices and patient assessment tools into clinical practice to evaluate the severity of itch at baseline and during follow-up, including documenting these evaluations in EMR systems. 
  • OUTLINE treatment plans that prioritize measurable itch symptom relief by incorporating targeted therapies and individualized patient care strategies. 

Accredited Provider

This activity is jointly provided by Global Education Group and Iridium Continuing Education.

AMA PRA Category 1 Credit™

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium CE. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Designation Statement
Global Education Group designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hours including 0.0 pharmacotherapeutic contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosures of Relevant Financial Relationship(s)

​Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
The planners and managers have the following relevant financial relationships with ineligible companies:

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

The planners and managers at Iridium CE have no relevant financial relationships to disclose.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Adelaide Hebert,
MD
Memorial Hermann-Texas Medical Center
The University of Texas MD Anderson Cancer Center
Bellaire, TX
Contracted Research (Principal Investigator's must provide information, even if received by the institution): Amgen, Arcutis, Dermavant, Pfizer 
Honoraria: Amgen, Apogee, Arcutis, Dermavant, Pfizer

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:
  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher
A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

System Requirements

System requirements
This educational activity is supported by an independent educational grant from Incyte Corporation and Sanofi and Regeneron Pharmaceuticals.

Maximum Credit Amount: 1.00

Credit Type: ACCME, ANCC
Release: 3/31/2025
Expiration: 3/31/2026